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Yulan Ren1,2, Boer Shan1,2, Daren Shi1,3 and Huaying Wang1,2*Abstract
Background: Salvage cytoreductive surgery (SCR) has been shown to improve the survival of cancer patients. This
study aimed to determine the survival benefits of SCR for recurrent endometrial cancer in Chinese population.
Methods: Between January 1995 and May 2012, 75 Chinese patients with recurrent endometrial cancer undergoing
SCR were retrospectively analyzed.
Results: 43 patients (57.3%) had R0 (no visible disease), 15 patients (20.0%) had R1 (residual disease ≤1 cm), and 17
(22.7%) had R2 (residual disease >1 cm) Resection. 35 patients (46.7%) had single, and 40 (53.3%) had multiple sites
of recurrence. The median survival time was 18 months, and 5-year overall survival (OS) rate were 42.0%. Multivariate
analysis showed that residual disease ≤1 cm and high histology grade were significantly associated with a better OS.
The size of the largest recurrent tumors (≤6 cm), solitary recurrent tumor, and age at recurrence (≤56 years old) were
associated with optimal SCR.
Conclusion: Optimal SCR and high histology grade are associated with prolonged overall survival for patients with
recurrent endometrial cancer. Patients with young age, tumor size < 6 cm, and solitary recurrent tumor are more likely
to benefit from optimal cytoreductive surgery.
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Endometrial carcinoma is a common gynecological can-
cer and the majority of patients present at an early stage
with a good long-term prognosis. However, about 13%
of patients with endometrial cancer develop recurrent
disease, and they have a very poor outcome with a mor-
tality of about 25% [1,2].
Treatment options for recurrent endometrial cancer
vary according to the distribution of recurrent disease.
Chemotherapy is often recommended for patients with
distant or widely metastatic recurrences, while radiother-
apy is recommended for patients with small, isolated
pelvic recurrences who have not received radiation [3,4].
For surgery, pelvic exenteration is recommended for
the treatment of a localized central pelvic recurrence
refractory to radiation therapy [5,6], while the benefit* Correspondence: huaying_wang@yahoo.com
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unless otherwise stated.of salvage cytoreductive surgery (SCR) in patients with
recurrent endometrial cancer is not confirmed. Several
recent reports reported that selected patients with resect-
able recurrent endometrial cancer could benefit from
complete SCR [7-10]. Therefore, the surgical indications
and selection criteria are urgently needed to minimize the
complications and mortality associated with surgery.
In this retrospective study, we evaluated the survival
benefit and the safety of SCR for Chinese patients with
recurrent endometrial cancer, and tried to define the
selection indications for SCR.Methods
Ethics statement
The study was approved by Ethics Committee of Fudan
University. All patients who participated in the study
signed informed consent forms.Study design
All patients with recurrent endometrial cancer undergoing
second SCR at the Department of Gynecologic Oncology. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tween January 1995 and May 2012 were identified from a
search of FUSCC Endometrial Cancer database. Patients
with nonepithelial tumors (eg. sarcoma) were excluded.
Recurrence was defined as a regrowth of tumor at least
3 months after the completion of primary therapy.
Patient data were abstracted retrospectively from in-
patient and outpatient medical records, including clin-
ical, surgery, and pathology reports of both primary and
secondary surgeries. All patients were restaged by the
International Federation of Gynecology and Obstetrics
(FIGO) stage 2009 [11]. Progression free interval (PFI) was
defined as the time from primary surgery to the diagnosis
of recurrence. The level of cytoreduction for recurrent
endometrial cancer was defined as: R0, complete resection
with no visible disease; R1, residual disease ≤1 cm; R2,
residual disease >1 cm.
The recurrent sites were categorized as solitary and
multiple. Patients were divided into two groups according
to the detection of recurrence: symptomatic, and asyp-
tomatic groups.
All patients were followed up at least 3 months after
surgery. Two patients died 2 months after SCR, and one
patients lost follow-up after hospital discharge. The median
follow-up duration was 18 months (range: 2–112 months).Statistical analysis
The primary statistical endpoints were overall survival
(OS) calculated from the date of SCR to the date of
death or last follow-up and progression-free survival
(PFS) from the date of SCR to the date of progression of
disease. The chi-square test was used for discrete and
binomial data. Stepwise logistic regression was used to
analyze the correlations between clinico-pathological
variables and SCR outcome. Survival curves were esti-
mated by Kaplan–Meier method and compared using
the log-rank test. Multivariate analysis was performed by
Cox proportional hazards regression model. P < 0.05 was
set to be significant. All statistical analyses were performed
using SPSS software (version 11.0).Results
Patient characteristics
Total 75 patients with recurrent endometrial cancer who
underwent surgery during the study period were identi-
fied. Clinico-pathological characteristics were summa-
rized in Table 1. Median age at the first surgery was
55 years old (range: 31–75). At the first surgery, 53 (70.7%)
patients had stage I disease (FIGO 2009), 5 (6.7%) had
stage II, 13 (17.3%) had stage III, and 4 (5.3%) had stage
IV disease. Sixty-five (85.7%) patients were diagnosed
with endometrioid adenocarcinoma, and 10 (13.3%) pa-
tients with non-endometrioid adenocarcinoma, including6 papillary serous cancer, 3 clear cell cancer, and 1 squa-
mous cell cancer.
At the first surgery, ECOG scores were no more than
2, including 0 in 6 patients, 1 in 62 patients, and 2 in 7
patients. Twenty-seven (36.0%) patients received total hys-
terectomy with bilateral salpingoopherectomy (TH/BSO),
10 (13.3%) received radical hysterectomy with bilateral
salpingoopherectomy (RH/BSO), 12 (16.0%) received
TH/BSO and pelvic lymphadenectomy (PL), 15 (20.0%)
received RH/BSO/PL, 4 (5.3%) received TH/BSO/PL
and para-aortic lymphadenectomy, 7 (9.3%) received TH/
BSO and cytoreduction surgery. For patients requiring
primary cytoreductive surgery, an optimal resection was
obtained in all patients. After the first surgery, 48 (64%)
patients received adjuvant therapy, including 33 (44.0%)
patients with chemotherapy, 5 (6.7%) with radiotherapy,
6 (8.0%) with both chemotherapy and radiotherapy, and
4 (5.3%) with hormonal therapy.
Median PFI was 18 months (range: 3–372). Median
age at recurrence was 56 years old (range: 33–76). In re-
currence, 30 patients were diagnosed without symptoms
at routine follow-up, and 45 patients with various symp-
toms, including vaginal bleeding or discharge (17 cases),
abdominal pain (16 cases), inguinal mass (3 cases), low-
degree fever (3 cases), constipation (3 cases), diarrhea
(1 case), hemoptysis (1 case), and lower limb edema
(1 case).
Before SCR, 24 cases were treated with chemotherapy,
4 cased with both chemotherapy and radiotherapy, and 1
case with radiotherapy. The most common regimens were
paclitaxel plus platinum, or platinum plus doxorubicin.Salvage cytoreductive surgery
Characteristics of recurrence and SCR were summarized
in Table 2. ECOG scores before SCR were no more than
3, including 0 in 30 patients, 1 in 25 patients, 2 in 15
patients, and 3 in 5 patients. During SCR, median largest
size of recurrence disease was 6 cm (range: 1–25). Re-
currence was found solitary in 35 (46.7%) patients and
multiple in 40 (53.3%) patients. Ascites were found in
8 (10.5%) patients with recurrence, with median ascites
volume 450 ml (range: 200–2400 ml). After SCR, 58
(77.3%) patients achieved optimal cytoreduction (residual
disease ≤1 cm). Nine (12.0%) patients developed peri-
operative complications, and no patient died during
perioperative period.
After SCR, 48 (64.0%) patients received salvage chemo-
therapy. The main regimen used was platinum plus taxol
(in 29 patients). Six (8.0%) patients received radiotherapy,
and 8 (10.7%) patients received both chemotherapy and
radiotherapy. Twenty (26.7%) patients received hormonal
therapy after SCR (5 alone, 15 combined with chemother-
apy and/or radiotherapy).
Table 1 Clinicopathological characteristics of patients and univariate analysis for OS after SCR
Cases Deaths Median OS (months) UVa analysis (P value)
Age at second surgery 0.549
≤56 years 38 15 60
>56 years 37 15 39
ECOG performance status at first surgery 0.352
0 6 1 48.00
1 62 25 62.124
2 7 4 34.00
Stage at first surgery (FIGO 2009) 0.760
Stage I-II 58 22 65.675
Stage III-IV 17 8 45.159
Pathological subtype 0.180
Endometrioid 65 28 57.753
Nonendometrioid 10 2 52.10
Histological grade
I 14 4 67.921 0.068
II 39 15 68.006 0.040*
III 22 11 44.819 Reference
Postoperative therapy after first surgery 0.309
Chemotherapy 33 14 53.51
Radiotherapy 5 2 36
CT+RT 6 1 72
Hormonal therapy 4 1 114
No 27 12 36.196
Symptoms at recurrence 0.723
Nonsymptomatic 30 13 54
Symptomatic 45 17 65
CA125 at recurrence 0.108
≤ 35 U/ml 25 7 69.650
>35 U/ml 35 18 35.733
Not available 15 5 77.548
Recurrence detection of nonsymptomatic 0.134
Imaging or CA-125 17 8 44.83
Physical examination 13 4 96
PFI 0.032*
≤18 months 40 19 34.963
>18 months 35 11 76.078
Largest size of recurrence 0.008*
≤ 6 cm 36 10 79.027
> 6 cm 39 20 35.918
Multiplicity of recurrence 0.144
Solitary 35 12 73.219
Multiple 40 18 37.295
Site of recurrence 0.056
Pelvisb and/or introabdomonal 63 23 66.186
Retroperitoneal 12 7 30.380
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Table 1 Clinicopathological characteristics of patients and univariate analysis for OS after SCR (Continued)
Ascites 0.048*
None 67 26 64.678
Yes 8 4 17.171
ECOG performance status before SCR 0.311
0 30 13 53.28
1 26 9 109.31
2 14 5 72.0
3 5 3 14.4
Residual disease after SCR
None 43 12 76.462 0.000*
0.1~1 cm 15 6 43.825 0.001*
1~2 cm 6 4 30.833 0.207
>2 cm 11 8 12.778 Reference
Postoperative therapy after SCR
Chemotherapy 48 22 40.192 Reference
Radiotherapy 6 1 114.0 0.045*
CT+RT 8 3 42.0 0.764
No 13 4 72.0 0.615
Note. a, UV, univariate; b, pelvis: including inguinal and vaginal; CT: chemotherapy; RT: radiotherapy; *P <0.05.
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During follow-up, 47 patients (62.7%) had disease pro-
gression. The median progression-free survival (PFS) was
9 months. The median survival was 18 months (range:
2–112 months). During follow-up, 30 (40.0%) patients
died of disease, 14 (18.7%) were alive with disease, and
31 (41.3%) were alive without disease.
Univariate analysis showed that the residual disease of
SCR, grade, PFI, the largest size of the recurrent tumors,
the multiplicity of the recurrent tumors, postoperative
therapy after SCR, and ascites were associated with the
post-recurrent survival (P < 0.05, Table 1). The median
survival of patients with R0, R1, and R2 were 76.5, 43.8,
and 21.8 months, respectively. The differences for strati-
fied comparisons between the outcomes of R0, R1, and
R2 were significant (R0 vs. R2: χ2 = 15.55, P = 0.00, R1 vs.
R2: χ2 = 5.45, P = 0.02) (Figure 1). In addition, the differ-
ences for stratified comparisons between the outcomes of
residual disease of ≤1 cm and >1 cm (χ2 = 15.55, P = 0.00)
were significant. However, there was no significant dif-
ference between residual disease of none and 0.1 ~ 1 cm
(χ2 = 0.465, P = 0.495), and there was no significant dif-
ference between residual disease of 1–2 cm and >2 cm
(χ2 = 1.592, P = 0.207). Therefore, residual disease of ≤1 cm
was considered optimal cytoreduction and analyzed in
multivariate analyses. The asymptomatic patients with
recurrence detected by imaging or CA-125 measure-
ments tended to have shorter survival than patients with
recurrence detected by physical examination (44.83 vs.96 months), but the difference was not significant
(P = 0.134). All variables with P < 0.01 in univariate
analysis were analyzed by multivariate analysis, and the re-
sults showed that residual disease after SCR and grade
were predictive factors for survival after SCR (P = 0.001
and P = 0.012, respectively).
Factors associated with the outcomes of SCR
After SCR, R0 resection was achieved in 43 (57.3%)
patients, R1 in 15 (20.0%) patients, and R2 in 17
(22.7%) patients.
In univariate analysis, the age at recurrence, the size of
the largest recurrent tumors, the site of recurrence
(retroperitoneal or not), and multiplicity of recurrence
were associated with optimal cytoreduction (R0 and R1)
(P = 0.013, 0.022, 0.086, and 0.03, respectively). Multi-
variate analysis showed that the age at recurrence, the
size of the largest recurrent tumors, and multiplicity of
recurrence were associated with the optimal cytoreduc-
tion (P = 0.046, 0.028, and 0.044, respectively) (Table 3).
Stage at primary surgery, grade, symptoms at recurrence,
pathological subtype, PFI, and ascites at recurrence were
not predictors of SCR outcomes.
Discussion
The treatment for recurrent endometrial cancer varies
depending on the recurrent location, the extent of dis-
ease, and prior therapy used. For patients with a local-
ized vaginal recurrence and no previous irradiation,
Table 2 Characteristics of recurrence and second
debulking surgery
Number of patients (%)
Largest size of recurrence (cm)
Median (range) 6 (1-25)
Sites of recurrence
Central pelvic-vaginal 6 (8.0)
Pelvic 25 (33.3)
Intro-abdorminal alone 3 (4.0)
Retroperitoneal alone 8 (10.7)
Pelvic and intra-abdominal 17 (22.7)
Pelvic and retroperitoneal 3 (4.0)
Intra-abdominal and retroperitoneal 1 (1.3)
Vaginal 5 (6.7)
Inguinal 5 (6.7)







Tumor mass resection 36 (51.4)
Pelvic lymph node resection 12 (16.0)
Para-aortic lymph node resection 10 (13.3)




Large-bowel resection 19 (25.0)
Small-bowel resection 6 (8.0)
Colostomy 6 (8.0)
Patial abdominal wall resection 3 (4.0)
Upper vaginectomy 18 (24.0)
Vulvectomy 1 (1.3)
Partial urethrectomy 1 (1.3)
Partial cystectomy and ureterectomy 2 (2.7)
Ureteral stents 6 (8.0)
Partial gastrectomy 1 (1.3)
Radical pulmonary lobe resection 1 (1.3)
Biopsy alone 4 (5.3)
Operative time (minutes)
Median (range) 150 (30-430)
Blood transfusion 42 (56.0)
Median (range, blood unit) 2 (1-13)
Median hospitalized day 20 (6-130)








Iliac artery injury 1 (1.33)
Ureteral injury 2 (2.67)
Acute renal failure 1 (1.33)
Urethrovaginal fistula 1 (1.33)
Bowel obstruction 1 (1.33)
Deep vein thrombosis 1 (1.33)
Drug allergy 1 (1.33)
Hydronephrosis 1 (1.33)
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trol and 5-year survival rate of 31-53% [12,13]. The
majority of patients with recurrence are treated with
palliative chemotherapy, and/or hormonal therapy. The
commonly used chemotherapy included cisplatin, carbo-
platin, doxorubicin, paclitaxel, and topotecan, with over-
all response rate ranging from 20% to 37% [14-18]. The
response rate of hormonal therapy with progestational
agents, anti-estrogens, and gonadotropins-releasing hor-
mone analogs are generally low, ranging from 9% to
16% [19-21]. Surgical resection for recurrent endometrial
cancer has traditionally been limited to a selected group
of patients presenting with a central pelvic recurrence
within a previously irradiated pelvic field. However, only
few patients are candidates for this approach [5,6].
To date, only 4 nonrandomized, retrospective studies
have investigated the outcomes of cytoreductive surgery
for recurrent endometrial cancer [7-10] (Table 4). A meta-
analysis on these 4 studies was performed to determine
the use of cytoreductive surgery [22]. Patients undergoing
optimal surgical cytoreduction (ranging from <2 cm to
no gross residual disease) had an overall survival advan-
tage. However, the subset with no gross residual disease
(complete surgical cytoreduction) was associated with
improved survival [22]. In this study, we confirmed the
survival benefit of patients with optimal cytoreduction.
In multivariate analysis, residual disease after SCR and
grade were found to be the predictive factors for survival
after SCR. Especially, residual disease was the strongest
survival determinant for recurrent endometrial cancer
(P = 0.001).
In previous studies, the definition of optimal cytore-
duction was ≤1 cm or ≤2 cm. In this study, we found
that patients with ≤1 cm residual disease had significant
Figure 1 Survival curve of residual disease after second debulking surgery.
Ren et al. BMC Cancer 2014, 14:135 Page 6 of 8
http://www.biomedcentral.com/1471-2407/14/135survival benefit from cytoreductive surgery, compared
with the patients with >1 cm residual disease (χ2 = 15.55,
P = 0.00), while there was no difference in survival be-
tween patients with none disease and 0.1-1 cm (χ2 = 0.465,
P = 0.495), and between 1–2 cm and >2 cm (χ2 = 1.592,
P = 0.207). Therefore, residual disease of ≤1 cm was
considered optimal cytoreduction and pooled together
for analysis. These data suggest that the definition of
optimal cytoreduction might be <1 cm, but further
studies employing larger samples are needed to confirm
this definition.
On the other hand, careful selection of the patients is
important due to the complications of SCR. In this study
we attempted to predict the optimal cytoreduction. The
factors associated with optimal cytoreduction in recur-
rent endometrial cancer were identified by logistic re-
gression analysis. In univariate analysis, the age, PFI, the
size of the largest recurrent tumors, the site of recur-
rence, and multiplicity of recurrence were associated
with optimal cytoreduction, which indicates that patients
with younger age, longer PFI, smaller tumor size, and re-




Age at second surgery (>56 years) 0.013*
Sites of recurrence (multiple) 0.030*
Largest size of recurrence (> 6 cm) 0.022
Site of recurrence (retroperitoneal) 0.086
Note. UV, univariate; MV, multivariate; 95%CI, 95% confidence interval; *P <0.05.are more likely to achieve optimal cytoreduction. How-
ever, in multivariate analysis, only the age, the size of the
largest recurrent tumors, and multiplicity of recurrence
were associated with the optimal cytoreduction. There-
fore, patients with young age (<56 years old), small
tumor size (<6 cm) and solitary recurrence are more
likely to achieve optimal cytoreduction and gain benefit.
After SCR, the patients who received radiotherapy
after SCR showed better OS than patients with chemo-
therapy (p = 0.045). The reason may be due to the fact
that more than half of the patients (48 cases, 64%) re-
ceived chemotherapy with widely disseminated tumor,
and only 6 patients received radiotherapy with the dis-
ease localized to vagina or vulva. However, adjuvant
therapy did not show significance in multivariate ana-
lysis. In a previous study the median survival of symp-
tomatic patients was longer than that of asymptomatic
patients (27 vs. 12 months); although the difference was
not statistically significant [23]. Consistent with this, we
found that the median survival of symptomatic patients
was longer than that of asymptomatic patients (65 vs.
54 months), but the difference was not statisticallysociated with residual disease at second
MV regression




















Scarabelli [7] 20 16.9 20 NA No gross 65 (13/20) 12 Undefined
Campagnutta [8] 75 13 75 19 <=1 74.7 (56/75) 53 9
Bristow [9] 61 18.5 35 28 No grossly visible 65.7 (23/35) 39 13.5
/ 26 13 / / / /
Awtrey [10] 27 20 27 35 <=2 67 (18/27) 43 10
This study 75 18 75 18 <=1 77.3(58/75) 72 22
Note. NA, not assessable. PFI, progression free interval. OS, overall survival.
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tients with recurrence detected by imaging or CA-125
measurements tended to have shorter survival than pa-
tients with recurrence detected by physical examination
(44.83 vs. 96 months), but the difference was not signifi-
cant (P = 0.134). Therefore, early detection of recurrence
by imaging and CA-125 measurements can not improve
prognosis. Routine follow-up for these patients is neces-
sary to detect recurrence by physical examination.
A dramatic survival advantage of SCR was observed in
carefully selected patients. However, due to the radical
procedures involved, the incidence of major surgical
complications and deaths should be concerned. Accord-
ing to the literatures, the rate of complications varied
from 25% to 62.7% (Table 5) [7-10]. In our study, total 9
patients (12.0%) developed perioperative complications,
including 1 iliac artery injury, 2 ureteral injury, 1 acute
renal failure, 1 urethrovaginal fistula, 1 bowel obstruc-
tion, 1 deep vein thrombosis, 1 hydronephrosis, and 1
drug allergy, while 42 patients (56%) received blood
transfusion during surgery. No patient died during peri-
operative period. The rate of complication in our study
was similar to previous studies with blood transfusion
included. Therefore, SCR was safe and acceptable in gen-
eral, but the incidence of severe complications should be
concerned. One study reported two (10%) perioperative
deaths after 21 and 30 days, one of them had a history of
cerebrovascular and hypertensive disease and developed
postoperative hemorrage which required reintervention
within 18 h of surgery [7]. In another study, one patient
with diffuse carcinosis died after surgery, whereas five
other patients (three with diffuse carcinosis) died in theTable 5 Summary of complications of SCR
Cases Complications Pa
Scarabelli [7] 20 3 (15%)
Campagnutta [8] 75 23 (30.7%)
Bristow [9] 35 13 (37.1%)
Awtrey [10] 27 17 (62.7%)
This study 75 9 (12%)
Note. BT, Blood transfusion.hospital postoperatively [8]. In this study, four patients
with diffuse carcinosis died postoperatively. These data
suggest that in patient with carcinosis it is not suitable
to perform SCR, and adequate preoperative evaluation
is necessary to reduce the rate of perioperative death.
In this study, optimal median OS was significantly lon-
ger than that reported in previous studies, but there is
no much difference in OS (Table 4). Several reasons may
account for it: first, the definition of optimal cytoreduc-
tion varied in different studies (ranging from <2 cm to
no gross residual disease), which influences OS with op-
timal cytoreduction. Second, the selection of patients is
different among different studies. For example, 9 patients
who had resection of non-abdominal disease and 13 pa-
tients who underwent a pelvic exenterative procedure
were excluded in one study [10]. In this study, 4 patients
receiving inguinal lymph node resection were included,
who had much better OS than patients with abdominal
recurrence if optimal cytoreduction was achieved.
There are several limitations of our study. First, the
number of patients enrolled in this study is small, due
to the infrequency of recurrent endometrial cancer.
Therefore, the selection criteria for SCR need to be
confirmed in further study. Second, there is a potential
for selection bias because our study is retrospective.
Prospective study is necessary to identify the appropri-
ate candidates for SCR. Third, we failed to collect the
data of the patients who did not undergo cytoreduction
and compare them to the patients enrolled in this
study, which would strengthen our conclusion that pa-
tients with recurrent endometrial cancer would benefit
from SCR.tients with BT BT unit Perioperative deaths
Not known 1.8 (0–5) 2 (10%)
Not known 1.3 (0–8) 1 (1.3%)
10 (28.6%) 3 (1-6) None
9 (33.3%) Not known None
42 (56%) 2 (1-13) None
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Based on our data, we get the following conclusions.
First, patients with residual disease less than 1 cm could
benefit from optimal SCR with prolonged overall survival.
Second, patients should be carefully selected before the
surgery, as patients with younger age, tumor size less than
6 cm, and single recurrence are more likely to achieve
satisfied cytoreduction. Third, complications of SCR are
not common but should be considered.
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